| Business Summary |
| A biopharmaceutical company, which is engaged in the design, discovery and development of NNR Therapeutics, a new class of drugs for the treatment of diseases and disorders of the central nervous system. |
| General Information |
200 East First Street
Suite 300
Winston-Salem, NC 27101
|
| www.targacept.com |
| Industry : Drugs |
| Sector: Health Care |
| Employees: 112 |
| CEO: Dr. J. Donald deBethizy, |
| Short Interest |
| Current Month (Mil) |
0.35 |
| Previous Month (Mil) |
0.27 |
| Short Interest Ratio (Days) |
1.10 |
| Management Effectiveness |
| Return on Equity |
n.a. |
| Return on Assets |
-22.00 |
| Return on Investments |
-37.00 |
| Profitability |
| Gross Margin |
n.a. |
| EBIT Margin |
-64.90 |
| Profit Margin |
-65.40 |
Connect with TheStreet